NattoPharma Awarded New Patent for Vitamin K2

Patent for benefits supporting cardiovascular applications of MenaQ7® Vitamin K2
OSLO, NORWAY and METUCHEN, NJ (June 14th 2016) – NattoPharma ASA has been
awarded a patent that allows the company to claim that MK-7 inhibits or reduces
the incidence of age-related hardening of the arteries in individuals with
cardiovascular conditions. The patent covers providing an effective amount of
vitamin K in combination with vitamin D to reduce the incidence of age-related
stiffening of arteries in doses appropriate to dietary supplement ranges, as
well as food and beverage products. This U.S. patent (no. 9364447 re.
“Compositions for treating or preventing cardiovascular disease”) was approved
on June 14, 2016.

“Being awarded this patent clearly validates the discovery of the cardiovascular
benefits of vitamin K2 made by the researchers with whom NattoPharma has had
pleasure of working with for years,” says NattoPharma CEO Daniel Rosenbaum. “The
issuing of this patent further legitimizes the clinical benefits that show the
cardio-protective benefits vitamin K2 delivers by even reversing age-related
hardening of the arteries. We anticipate exploring opportunities for growth
through dietary supplements and functional/fortified foods, as well as future
cardiovascular pharmaceutical applications as a result of this intellectual
property.”

NattoPharma has invested considerable resources in technology development and
patenting around vitamin K2, and that the company is actively using and will use
patents—through patent life—as a competitive advantage for companies that buy
NattoPharma’s MenaQ7® Vitamin K2 as MK-7.

# # #

About MenaQ7®

MenaQ7® is the best documented, commercially available vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. MenaQ7® is available in two varieties: natural
vitamin K2 as MK-7 Crystals and nature-identical synthetic vitamin K2 as MK-7
PURE. For more information on the health benefits of MenaQ7, visit menaq7.com.

About NattoPharma

NattoPharma ASA, based in Norway, is the  world’s leader in vitamin K2 research
and development. NattoPharma is the exclusive international supplier of MenaQ7®
Vitamin K2 as MK-7, and has a multi-year research and development program to
substantiate and discover the health benefits of vitamin K2 for applications in
the marketplace for functional food and dietary supplements. With a global
presence, the company established its North American subsidiary, NattoPahrma
USA, Inc., in Meuchen, NJ. For more information, visit nattopharma.com.

For more information, please contact:

Kate Quackenbush, Director of Communications

NattoPharma USA, Inc.

Phone: 609-643-0749

E-mail: kate.quackenbush@nattopharma.com